BioSpace News Archive

The program has awarded 5 startups in two therapeutic areas, Central Nervous System and Respiratory, with seed investments of up to 100,000 euros and the chance to start a strategic partnership with Zambon

Days after Axovant announced an end to focusing on its legacy small molecule portfolio in favor of gene therapies, the company announced it has licensed worldwide rights to two gene therapy programs from the University of Massachusetts School of Medicine.

2nd Deadliest Outbreak in History Highlights the Need for a Safe and Effective Vaccine

Earlier this week, the U.S. Food and Drug Administration cleared the company’s Investigational New Drug Application to allow the company to initiate clinical studies with Xeno-Skin, a product designed to provide help for patients who have suffered from significant burns.

In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.

Charles Morris, chief medical officer for Waltham, Mass.-based Radius Health, is eying the day that there will be better outcomes for breast cancer patients who have developed tumors resistant to current treatments. If things continue to go well, Radius may be able to provide those options.

MorphoSys AG reported today that its licensee Janssen has announced that results from the ECLIPSE study demonstrated that Tremfya(R) (guselkumab) was superior to Cosentyx(R) (secukinumab) in treating adults with moderate to severe plaque psoriasis for the primary endpoint of a PASI 90 response at week 48.

Researchers at UCSF recently published research in the journal Science describing their use of a modified version of CRISPR gene editing to stimulate the activity of certain genes, resulting in the prevention of severe obesity in mice who had a genetic predisposition to extreme weight gain.

CARMAT today announces the appointment of Pascale d’Arbonneau as Chief Financial Officer.

Because many types of prostate cancer are very slow growing and generally diagnosed in older men, so-called “watchful waiting” is often the prescribed treatment plan. Now researchers are saying this may not be the best way.